Categories
Uncategorized

SilverCrest Metals Inc. (NYSE:SILV) 06 May: The latest news at a glance

SilverCrest Metals Inc. (NYSE:SILV), closed the day at $7.11, a fall of 0 per cent and a stock price that brought its market cap to $904.58 million. The 52-week range for the stock was 2.96 – 8.30 that put its current price at a premium of 140.2% to the 52-week low price whereas it is trading at a discount of -14.34% to the 52-week high price.

VANCOUVER, BC – April 24, 2020 / SELL SIDE ANALYST / — SilverCrest Metals Inc. (NYSE:SILV) on April 24, 2020 announced that it has closed the private placement with SSR Mining Inc. (“SSR Mining”) previously announced on April 21, 2020 pursuant to which SSR Mining elected to exercise its equity participation right. SSR Mining purchased 3,597,291 common shares of the Company at a price of C$7.50 per share for a total investment of C$26,979,682.50. The common shares have a statutory hold period of four months and one day expiring August 25, 2020.

As previously announced on April 17, with the closing of the non-brokered private placement offering and exercise by SSR Mining of its equity participation right, SilverCrest is in a robust financial position to advance the high-grade precious metal Las Chispas Project in Sonora, Mexico with a cash balance of C$234 million in its treasury. In conjunction with closing of the SSR Mining placement, SSR Mining has advised SilverCrest that it has entered into a transaction for resale of the common shares with 2176423 Ontario Ltd., a corporation beneficially controlled by Mr. Eric Sprott. For further details on this transaction, please see news release dated April 21, 2020.

The Other Industrial Metals & Mining company’s EPS for trailing 12 months is -$0.07 and it is estimated to be posting an EPS of $17.38 for the current quarter. The outstanding share count is 127.23 million shares but the size of available float is 95.07 million shares. The stock’s current price is trailing SMA-200 by 18.45% which is also 19.46% up from SMA-50. Reducing that period to a shorter term, we see the price is trailing 13.22% to the SMA-20. Volatility for the week was 6.59%, which was 7.56% in the previous month.

The company closed the session with a trading volume of 496.01 thousand shares, below from its average daily trading volume of 1.22 million. When looking at performance, we see the stock demonstrating a weekly performance of 0.57% while keeping a monthly performance of 34.4%. Quarterly performance saw a rise of 13.04% but succeeded to record a yearly performance of 131.6% while showing YTD performance of 5.49% which was 26.96% for last six months.

Categories
Uncategorized

News Brief: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), finished the day at $0.87, a drop of -2.45 per cent and a price that brought its market cap to $111.78 million. The Biotechnology company is currently upholding a gross margin of 86.8%. The company’s EPS for trailing 12 months is -$0.55 and it is estimated to be posting an EPS of -$0.1 for the current quarter.

WATERTOWN, Mass., May 7, 2020 / SELL SIDE ANALYST / — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), on March 2, 2020, announced positive topline 36-month follow-up data from the second Phase 3 trial of YUTIQ®(fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. “The durable 36-month follow-up data from the second Phase 3 trial of YUTIQ highlight its long-term ability to reduce uveitic flares, consistent with the findings from the first Phase 3 trial. Reduction of uveitic flares is a key component in the treatment of this devastating disease leading to progressive vision loss and blindness, thus the recurrence rate of 46.5% at 36-months is compelling,” said Dr. Thomas Albini, Professor of Clinical Ophthalmology at Bascom Palmer Eye Institute in Miami, Florida. “Safety data showed no unanticipated side effects at each follow-up timepoint at 12-, 24-, and 36-months. These promising efficacy and safety data, coupled with a one-time administration, further position YUTIQ as a new, innovative treatment alternative for patients suffering from chronic non-infectious uveitis affecting the posterior segment of the eye.”

Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals said “We continue to believe YUTIQ is a differentiated treatment option compared to existing therapies because of its highly efficacious and solid safety profile, coupled with its convenient, single administration and long-term consistent dosing of drug. The 36-month results provide additional support in its long-acting potential, a characteristic consistently regarded by treating physicians as a critical treatment advantage. Our commercial efforts are yielding increased reception and adoption from uveitis specialists across the U.S., as well as positive patient feedback on the YUTIQ product profile.” The second double-masked, randomized Phase 3 trial of YUTIQ enrolled 153 patients in 15 clinical centers in India, with 101 eyes treated with YUTIQ and 52 eyes receiving sham injections. At 36-months, the recurrence rate in YUTIQ randomized eyes was significantly lower than in sham treated eyes (46.5% vs. 75.0%, respectively; p=0.001). Visual acuity gains or losses of 3-lines or more were both similar between treatment groups. Considerably fewer YUTIQ-treated eyes (8.9%) needed the assistance of adjunctive intraocular/periocular injection medication for uveitic inflammation compared to sham treated eyes (51.9%); 31.7% of YUTIQ treated eyes needed the assistance of an adjunctive systemic steroid or immunosuppressant compared to 32.7% for sham treated eyes.

Intraocular pressure lowering drops were used in 74.3% of YUTIQ treated eyes and 73.1% of sham treated eyes. IOP lowering surgeries were performed in 2.0 % of YUTIQ treated eyes and in none in the sham treated eyes. In patients with phakic eyes when enrolled in the study cataracts were extracted from 70.5% of patients administered YUTIQ and 26.5% of patients administered sham by the final 36-month time point of the study. Macular edema was resolved in 75.8% of YUTIQ treated eyes and 53.8% of sham treated eyes that had edema recorded at baseline. Mean intraocular pressure (IOP) at 36 months was 14.8 mmHg and 13.4 mmHg in the YUTIQ treated eyes and sham treated eyes, respectively.

The Beta number showed the stock is subject to risk 42% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is -69.9% while ROE for the same period is -314%. The outstanding share count is 128million shares but the size of available float is 123.72 million shares. The stock’s current price is lagging SMA-200 by -42.64% which is also -13.12% down from SMA-50. Reducing that period to a shorter term, we see the price is also lagging -3.06% to the SMA-20. Volatility for the week was 8.43%, which was 0.26% in the previous month. The company closed the session with a trading volume of 498.42 thousand shares, below from its average daily trading volume of 772.91 thousand. It has been generating revenue of $20.4 million while net income posted by the company in last 12 months was -$56.8 million.

When looking at performance, we see the stock demonstrating a weekly performance of -15.21% while keeping a monthly performance of 10.98%. Quarterly performance saw a drop of -54.28% and continued the negative trend with a yearly performance of -47.39% while showing YTD performance of -43.66% which was -62.84% for last six months. The 52-week range for the stock was 0.70 – 2.69 that put its current price at a premium of 24.76% to the 52-week low price whereas it is trading at a discount of -67.54% to the 52-week high price.

Categories
Uncategorized

Recent Stock News: cbdMD, Inc. (NYSE:YCBD)

cbdMD, Inc. (NYSE:YCBD), concluded the day at $0.95 after seeing a fall of -1.82% that brought its market cap to $45.8 million. The Marketing Services company is currently upholding a gross margin of 62% while its EPS for trailing 12 months is -$1.84 and it is estimated to be posting an EPS of -$0.08 for the current quarter.

On February 10, 2020, cbdMD, Inc. (NYSE:YCBD) announced  announced the execution of a non binding letter of intent to form a joint venture (“JV”) with Better Choice Company, Inc. (OTCQB: BTTR). Subject to the negotiation and execution of definitive agreements both parties intend to contribute certain CBD animal health related assets, including brands, CBD supply, logistics, service agreements, intellectual property, back office support and other assets with the mutual goal of expanding their respective hemp derived CBD pet brands, in exchange for 50% ownership in the newly formed JV. Initially, the JV will be focused on launching “Halo Hemp”, “powered by cbdMD”, which will be manufactured by Better Choice utilizing cbdMD’s CBD supply. Both parties will leverage their sales teams, marketing capabilities, online presence, and distribution channels to maximize the economies of scale of the partnership.

Chairman of the Board of Better Choice, Michael Young stated, “In a very short period of time, the team at cbdMD has built two award-winning and market leading brands along with a comprehensive CBD infrastructure. Better Choice’s entry into the hemp derived CBD pet market, through our brands, including recently acquired Halo, could be accelerated through a partnership with the cbdMD team. In doing so, the to be formed JV will benefit by integrating our sales capabilities into well-established distribution channels, which includes major retailers. The CBD pet market is at the very early stages and there is more than enough room for several brands to become leaders the marketplace. In working together, we can leverage each other’s strengths.”

“We are proud to have established a secure supply chain with dedicated, 2018 Farm Bill compliant, hemp farms and extraction facilities to ensure the highest quality and integrity of the raw materials we use. Our staff of over 40 full time sales consultants are rapidly growing our distribution channels. We are also in the process of obtaining our NASC certification, which many larger retailers in the pet industry require for product placement. We believe this potential joint venture with Better Choice will help accelerate our goal of big box retail deployment,” said Martin Sumichrast, Chairman & Co-CEO of cbdMD, Inc.

In the trailing twelve months, its has seen an average of -120.8% return on investment (ROI). The outstanding share count is 48.42 million shares but the size of available float is 31.96 million shares. The stock’s current price is lagging SMA-200 by -64.28% which is also 8.47% up from SMA-50. Reducing that period to a shorter term, we see the price is trailing 11.72% to the SMA-20. Volatility for the week was 11.95%, which was 12.72% in the previous month. The company closed the session with a trading volume of 497.28 thousand shares, below from its average daily trading volume of 807.46 thousand. It has been generating revenue of $33.3 million while net income posted by the company in last 12 months was -$30.8 million.

When looking at performance, we see the stock demonstrating a weekly performance of 16.05% while keeping a monthly performance of 9.7%. Quarterly performance saw a drop of -9.06% and continued the negative trend with a yearly performance of -83.94% while showing YTD performance of -58.15% which was -74.16% for last six months. The 52-week range for the stock was 0.50 – 7.24 that put its current price at a premium of 88.41% to the 52-week low price whereas it is trading at a discount of -86.94% to the 52-week high price.

Categories
Uncategorized

Notable News in Brief: Bio-Techne Corporation (NASDAQ:TECH)

Bio-Techne Corporation (NASDAQ:TECH), settled the day at a share price of $227.54 after seeing a rise of 1.13% that brought its market cap to $8.68 billion. The 52-week range for the stock was 155.17 – 229.00 that put its current price at a premium of 46.64% to the 52-week low price whereas it is trading at a discount of -0.64% to the 52-week high price. The Biotechnology company is currently upholding a gross margin of 66.2% while maintaining a net profit margin of 26.2%. Operating margin for the last 12 months remained 21.2%.

Bio-Techne Corporation (NASDAQ: TECH), on April 30, 2020, announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2020. The quarterly dividend will be payable May 22, 2020 to all common shareholders of record on May 11, 2020. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Sharing its business performance, Bio-Techne Corporation (NASDAQ: TECH) said that it is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.

The company’s EPS for trailing 12 months is $4.96 and its annual dividend yield is 0.56% with a payout ratio of 25%. It is estimated to be posting an EPS of $1.15 for the current quarter. The Beta number showed the stock is subject to risk 7.00% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is 10.2% while ROE for the same period is 16.2% and have seen an average of 6.9% return on investment (ROI). The outstanding share count is 38.17 million shares but the size of available float is 38.17 million shares. The stock’s current price is trailing SMA-200 by 12.15% which is also 18.46% up from SMA-50. Reducing that period to a shorter term, we see the price is trailing 12.31% to the SMA-20. Volatility for the week was 6.58%, which was 4.66% in the previous month.

The company closed the session with a trading volume of 492.35 thousand shares, above to its average daily trading volume of 257.85 thousand. It has been generating revenue of $744.7 million while net income posted by the company in last 12 months was $195.1 million.

When looking at performance, we see the stock demonstrating a weekly performance of 12.73% while keeping a monthly performance of 22.71%. Quarterly performance saw a rise of 8.37% but succeeded to record a yearly performance of 13.02% while showing YTD performance of 3.66% which was 8.78% for last six months.

Categories
Uncategorized

Stock News for Broadridge Financial Solutions, Inc. (NYSE:BR)

Broadridge Financial Solutions, Inc. (NYSE:BR), completed the trade at a price of $113.06 after seeing a change of -2.53% that brought its market cap to $12.97 billion. The outstanding share count is 114.7 million shares but the size of available float is 114.04 million shares. The stock’s current price is lagging SMA-200 by -5.45% which is also 9.45% up from SMA-50. Reducing that period to a shorter term, we see the price is trailing 6.08% to the SMA-20. Volatility for the week was 2.65%, which was 3.12% in the previous month.

On March 2, 2020, Broadridge Financial Solutions, Inc. (NYSE:BR) has completed its previously announced acquisition of FundsLibrary, a leader in fund document and data dissemination in the European market. The acquisition accelerates Broadridge’s pan-European regulatory communications and digital data platform, supporting the lifecycle of fund data, documents, and regulatory reporting for the investment industry. FundsLibrary’s solutions enable fund managers to increase distribution opportunities and help them comply with regulations such as Solvency II and MiFID II. The business will be combined with FundAssist, Broadridge’s existing European funds regulatory communications business. The combination of FundsLibrary’s data platform and technology with Broadridge’s existing fund calculation, document creation and translation capabilities, creates an end-to-end solution for fund managers and distributors, enabling them to respond to demanding regulatory requirements across multiple jurisdictions. The combined business will be known as Broadridge Fund Communication Solutions, and will be led by Arun Sarwal, former CEO of FundsLibrary. Sarwal has extensive financial services industry and technology business leadership experience. He previously held roles as Senior Vice President of SS&C Technologies, CEO of DST Investment Management Solutions, COO at Scottish Widows Investment Partnership (SWIP), SVP within ABN AMRO’s Private Clients & Asset Management business and was one of the founders of Kurtosys Systems. 

“I am delighted to lead this exciting fund data and regulatory communications business for Broadridge as we expand and grow our footprint in international markets,” says Sarwal.  “This combined business will enable Broadridge clients to utilize a single provider for the creation and dissemination of fund marketing and regulatory documents so they can increase distribution opportunities and meet the demanding standards of regulation.” Broadridge Fund Communication Solutions provides a comprehensive digital platform, supporting the lifecycle of fund data, documents and regulatory reporting for the global investment industry. The company manages and distributes data for some 700 global fund groups and supports over 200 million fund data requests each year. It is recognized for the breadth of its regulatory solutions, encompassing production and distribution of reports, including Key Information Documents (UCITs KIID & PRIIP KID), MiFiD II and Solvency II, for clients globally in over 35 languages.

The company closed the session with a trading volume of 477.4 thousand shares, below from its average daily trading volume of 1.13 million. It has been generating revenue of $4.35 billion while net income posted by the company in last 12 months was $422million. When looking at performance, we see the stock demonstrating a weekly performance of 1.45% while keeping a monthly performance of 23.81%. Quarterly performance saw a drop of -5.11% and continued the negative trend with a yearly performance of -3.37% while showing YTD performance of -8.48% which was -9.45% for last six months.

The 52-week range for the stock was 81.90 – 136.99 that put its current price at a premium of 38.05% to the 52-week low price whereas it is trading at a discount of -17.47% to the 52-week high price. The Information Technology Services company is currently upholding a gross margin of 27.2% while maintaining a net profit margin of 9.7%. Operating margin for the last 12 months remained 13.2%.

The company’s EPS for trailing 12 months is $3.58 and its annual dividend yield is 1.91% with a payout ratio of 56.1%. It is estimated to be posting an EPS of $1.72 for the current quarter. The Beta number showed the stock is subject to risk -17% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is 10.5% while ROE for the same period is 36.2% and have seen an average of 20.3% return on investment (ROI).

Categories
Uncategorized

Top Stock News Story: Guidewire Software, Inc. (NYSE:GWRE)

Guidewire Software, Inc. (NYSE:GWRE), completed the trade at a price of $90.72 after seeing a change of 3.13% that brought its market cap to $7.65 billion. Volatility for the week was 3.52%, which was 4.18% in the previous month. The company closed the session with a trading volume of 489.1 thousand shares, below from its average daily trading volume of 911.75 thousand. It has been generating revenue of $701.2 million while net income posted by the company in last 12 months was -$20.5 million.

Guidewire Software, Inc. (NYSE: GWRE) along with Guidewire PartnerConnect Solution partner  and in collaboration with FRISS, on April 21, 2020, announced the FRISS add-on for Fraud Detection, created using the Guidewire DevConnect developer environment, has successfully completed the Ready for Guidewire validation process and is available for download by Guidewire customers in the Guidewire Marketplace. Insurance fraud is a global issue. In the US alone, the cost of insurance fraud exceeds $40 billion per year, costing the average family hundreds in increased premiums (FBI). According to the ABI, 1,300 insurance scams were uncovered every day in the UK in 2018 with the average fraudulent act costing £12,000.

“Fraud detection tools are becoming increasingly important to insurers. With the strain on the global economy, experts are predicting a rise in fraud rates,” says Karlyn Carnahan, Head of Celent’s North American Property Casualty business. “Pre-integration of fraud tools into a claims or policy admin system allows insurers to rapidly deploy these capabilities and stay ahead of the projected rise in fraudulent claims.” FRISS’ add-on tackles insurance fraud by helping insurers automatically check claims for potential fraud and risks at multiple stages of the claim workflow in Guidewire ClaimCenter. Claim scoring results, including actionable insights, are available to claims adjustors directly within ClaimCenter. As an integrated part of an established workflow this add-on ensures claims are screened consistently and processed automatically and quickly. In addition, claims adjustors or investigators can provide feedback on the scoring that supports ongoing training and improvement of the fraud models employed.

“As an established Guidewire PartnerConnect Solution partner, we are pleased to offer a new automated fraud detection solution. Co-developed and validated with a joint customer, our add-on combines AI and machine-learning with out-of-the-box expert knowledge rules,” said Bas de Graaf, Global Partner Manager, FRISS. “This add-on supports both operational excellence and digitalization within the claims process, making processes more efficient without losing the necessary controls. Like Guidewire, FRISS has a singular focus on P&C insurance. The combination of a proven core platform provider like Guidewire and an insurtech like FRISS offers insurers the best of both worlds.”

When looking at performance, we see the stock demonstrating a weekly performance of 2.69% while keeping a monthly performance of 9.2%. Quarterly performance saw a drop of -18.36% and continued the negative trend with a yearly performance of -14.82% while showing YTD performance of -17.35% which was -19.65% for last six months. The 52-week range for the stock was 71.64 – 124.16 that put its current price at a premium of 26.63% to the 52-week low price whereas it is trading at a discount of -26.93% to the 52-week high price.

The Business Software & Services company is currently upholding a gross margin of 53.3% while maintaining a net profit margin of -2.9%. Operating margin for the last 12 months remained -5.3%. The company’s EPS for trailing 12 months is -$0.26 and it is estimated to be posting an EPS of -$0.05 for the current quarter. The Beta number showed the stock is subject to risk 25% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is -0.9% while ROE for the same period is -1.3% and have seen an average of 0.5% return on investment (ROI). The outstanding share count is 84.29 million shares but the size of available float is 82.8 million shares. The stock’s current price is lagging SMA-200 by -12.64% which is also 0.04% up from SMA-50. Reducing that period to a shorter term, we see the price is trailing 8.14% to the SMA-20.

Categories
Uncategorized

Under The Radar Stock News: Sonoco Products Company (NYSE:SON)

Sonoco Products Company (NYSE:SON), settled the day at a share price of $50.61 after seeing a rise of 2.41% that brought its market cap to $5.1 billion. The company closed the session with a trading volume of 488.66 thousand shares, below from its average daily trading volume of 648.98 thousand. It has been generating revenue of $5.33 billion while net income posted by the company in last 12 months was $298.6 million.

Sonoco Products Company (NYSE: SON), on Feb. 26, 2020, came announcing that its recently acquired subsidiary TEQ Thermoform Engineered Quality, a global manufacturer of thermoformed packaging, serving healthcare, medical device and consumer markets, will rename and brand all its manufacturing locations strictly as TEQ. This includes facilities across Europe, currently branded as Plastique. The legal name will become SONOCO TEQ, with the appropriate company type dependent on the region of the facility. In January 2020, Sonoco, one of the most sustainable, diversified global packaging companies, completed the acquisition of Thermoform Engineered Quality, LLC, and Plastique Holdings, LTD, (together TEQ). The comprehensive rebrand will unite manufacturing locations globally and focus on creating a more seamless customer experience. TEQ operates three thermoforming facilities as well as one extrusion operation in the United States, a thermoforming operation in the United Kingdom, and thermoforming and molded-fiber manufacturing in Poland. Each facility has state-of-the-art cleanroom capabilities enabling the production of sterile, barrier packaging systems for pharmaceuticals and medical devices. In addition, TEQ produces recyclable, molded-pulp-fiber packaging and thermoformed plastic packaging for multiple consumer products.

“The rebranding of TEQ Thermoform Engineered Quality and Plastique to the TEQ name displays the evolution of how our brands have grown more cohesive to address the needs of our mutual customers,” said Todd McDonald, director of sales and marketing for TEQ. Fibrepak, the fiber molding division of TEQ, will retain its own separate brand identity. Fibrepak uses the latest ‘Cure-In-The-Mold’ technology to produce the highest quality, most well-defined fiber packaging available. Products differ from traditional molded pulp packaging in several ways. For example, the packaging boasts a high tolerance that enables accurate registration to ensure a consistent fit. The process also allows for thin walls, defined hinges and a smooth premium finish. TEQ has recently made significant investments at all their business locations. This includes building ISO 7 controlled environments certified to ISO 13485 at the facilities in Nottingham, United Kingdom, and Poznan, Poland. The company has also added Kiefel KMD 78’s in both locations, making them one of the largest users of Kiefel thermoforming machines in the world. Additionally, an extrusion facility has been installed at the manufacturing facility in Huntley, Ill. This expansion will help provide proprietary materials: TEQethylene, TEQpropylene and TEQconnex.

When looking at performance, we see the stock demonstrating a weekly performance of 7.59% while keeping a monthly performance of 7.84%. Quarterly performance saw a drop of -13.12% and continued the negative trend with a yearly performance of -19.74% while showing YTD performance of -18% which was -13.83% for last six months.

The 52-week range for the stock was 37.30 – 66.57 that put its current price at a premium of 35.68% to the 52-week low price whereas it is trading at a discount of -23.98% to the 52-week high price. The Packaging & Containers company is currently upholding a gross margin of 19.8% while maintaining a net profit margin of 6.1%. Operating margin for the last 12 months remained 9%. The company’s EPS for trailing 12 months is $2.95 and its annual dividend yield is 3.4% with a payout ratio of 52.2%. It is estimated to be posting an EPS of $0.79 for the current quarter. The Beta number showed the stock is subject to risk -16% more than the market as a whole.

In the trailing twelve months, its return on assets (ROA) is 6.5% while ROE for the same period is 17.9% and have seen an average of 10.7% return on investment (ROI). The outstanding share count is 100.68 million shares but the size of available float is 99.77 million shares. The stock’s current price is lagging SMA-200 by -9.8% which is also 5.48% up from SMA-50. Reducing that period to a shorter term, we see the price is trailing 5.94% to the SMA-20. Volatility for the week was 2.86%, which was 4.32% in the previous month.

Categories
Uncategorized

Notable news to read: Chatham Lodging Trust (NYSE:CLDT)

Chatham Lodging Trust (NYSE:CLDT), ended the day at $6.17, a fall of -1.28 per cent and a share price that brought its market capitalization to $304.37 million. Volatility for the week was 10.93%, which was 14.79% in the previous month. The company closed the session with a trading volume of 491.07 thousand shares, below from its average daily trading volume of 493.27 thousand. It has been generating revenue of $328.3 million while net income posted by the company in last 12 months was $18.4 million.

In an effort to safeguard shareholders value, Chatham Lodging Trust (NYSE: CLDT) decided to temporarily suspend dividends. On March 17, 2020, company announced that it has suspended its monthly dividend and will not declare a March dividend which would have been paid in April.

Commenting on the decision, Jeffrey H. Fisher, Chatham’s president and chief executive officer said “Facing unprecedented operating conditions in the travel industry and little visibility, we believe it is most prudent to suspend our monthly dividend as a means of preserving shareholder value. We are hopeful that the effects from COVID-19 will prove to be short-term and people will have the confidence to resume travel sooner rather than later. Our teams at Chatham and Island Hospitality have the experience to persevere through these situations, and we are thankful to have this platform that enables us to move aggressively and quickly. We are working vigorously to maximize revenue, and we are aggressively cutting operating costs and deferring all non-essential capital expenditures to minimize the adverse effects on cash flow.”

When looking at performance, we see the stock demonstrating a weekly performance of -13.59% while keeping a monthly performance of 2.32%. Quarterly performance saw a drop of -64.96% and continued the negative trend with a yearly performance of -68.38% while showing YTD performance of -66.36% which was -65.45% for last six months. The 52-week range for the stock was 3.44 – 20.66 that put its current price at a premium of 79.36% to the 52-week low price whereas it is trading at a discount of -70.14% to the 52-week high price.

The REIT – Hotel/Motel company is currently upholding a gross margin of 74.6% while maintaining a net profit margin of 5.6%. Operating margin for the last 12 months remained 17.3%. The company’s EPS for trailing 12 months is $0.39 and its annual payout ratio is 335.7%. It is estimated to be posting an EPS of -$0.01 for the current quarter. The Beta number showed the stock is subject to risk 86% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is 1.3% while ROE for the same period is 2.4% and have seen an average of 4.2% return on investment (ROI).

The outstanding share count is 49.33 million shares but the size of available float is 45.86 million shares. The stock’s current price is lagging SMA-200 by -60.81% which is also -35.94% down from SMA-50. Reducing that period to a shorter term, we see the price is also lagging -2.67% to the SMA-20.

Categories
Uncategorized

Notable news popped up Friday: NanoViricides, Inc. (NYSE:NNVC)

NanoViricides, Inc. (NYSE:NNVC), closed the day at $6.45, a rise of 1.1 per cent and a stock price that brought its market cap to $45.41 million. The company closed the session with a trading volume of 496.75 thousand shares, below from its average daily trading volume of 3.65 million. Net income posted by the company in last 12 months was -$7.8 million.

NanoViricides, Inc. (NYSE: NNVC), on January 24, 2020, unveiled that it has completed an underwritten public offering (the “Offering”) with gross proceeds of $8.625 million before deducting underwriting discounts and other estimated offering expenses. The Offering included 2.5 million shares of the Company’s common stock, and 375,000 additional shares from the exercise of the underwriter’s option to purchase to cover over-allotments at the public offering price of $3.00 per share. Aegis Capital Corp. acted as sole bookrunner for the offering. The net proceeds to the Company after underwriter’s commission and agreed upon customary fees and expenses were approximately $7.78 million, before deducting the Company’s legal and accounting expenses related to the Offering. The Company intends to use the net proceeds to fund general corporate purposes and to fund ongoing operations and to repay certain accounts payable to related parties. This Offering was made pursuant to an effective registration statement on Form S-1 (No. 333-235306) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on January 09, 2020. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering have been filed with the SEC.

Sharing the market size for the treatment of shingles, company said that it is estimated to be around one billion dollars by various estimates. These estimates take into account the Shingrix® vaccine as well as existing vaccines. About 500,000 to 1million cases of shingles occur in the USA alone every year. The market size for our immediate target drugs in the HerpeCide™ program is variously estimated at billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide™ program, namely, HSV-1 “cold sores” treatment, and HSV-2 “genital ulcers” treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials. These additional candidates are based on NV-HHV-101, thereby maximizing return on investments and shareholder value.

When looking at performance, we see the stock demonstrating a weekly performance of 20.79% while keeping a monthly performance of 34.37%. Quarterly performance saw a drop of -23.67% but succeeded to record a yearly performance of 22.81% while showing YTD performance of 156.97% which was 176.82% for last six months.

The 52-week range for the stock was 1.27 – 19.20 that put its current price at a premium of 407.35% to the 52-week low price whereas it is trading at a discount of -66.41% to the 52-week high price. The Biotechnology company’s EPS for trailing 12 months is -$2.08 and it is estimated to be posting an EPS of $0.01 for the current quarter. The Beta number showed the stock is subject to risk 12% more than the market as a whole.

In the trailing twelve months, its return on assets (ROA) is -60% while ROE for the same period is -78.1%. The outstanding share count is 7.04 million shares but the size of available float is 6.31 million shares. The stock’s current price is trailing SMA-200 by 39.44% which is also -5.81% down from SMA-50. Reducing that period to a shorter term, we see the price is trailing 12.45% to the SMA-20. Volatility for the week was 17.92%, which was 11.40% in the previous month.

Categories
Uncategorized

Recent Stock News: RenaissanceRe Holdings Ltd. (NYSE:RNR)

RenaissanceRe Holdings Ltd. (NYSE:RNR), concluded the day at $141.13 after seeing a fall of -2.26% that brought its market cap to $6.33 billion. The Property & Casualty Insurance company is currently upholding a net profit margin of 16.8%. Operating margin for the last 12 months remained 24.1%. The company’s EPS for trailing 12 months is $16.24 and its annual dividend yield is 0.99% with a payout ratio of 8.4%. It is estimated to be posting an EPS of $4.27 for the current quarter.

On February 4, 2020, RenaissanceRe Holdings Ltd. (NYSE:RNR) and AXA Liabilities Managers (AXA LM) came to an agreement to acquire RenaissanceRe (UK) Limited (RRUKL). The acquisition, which is expected to close later this year, is subject to regulatory approval and will be made through an investment vehicle managed by AXA LM.  Formerly known as Tokio Millennium Re (UK) Limited, the UK run-off business was acquired by RenaissanceRe as part of its purchase of Tokio Millennium Re in 2018.  RRUKL primarily wrote motor, casualty, political risk, engineering and marine treaty business until 2015, when it was placed into run-off.  Gross reserves as at 30 September 2019 were £160M.

Talking about the agreement, Sylvain Villeroy du Galhau, CEO of AXA LM, said “I am delighted to announce that we reached an agreement with RenaissanceRe to acquire their UK run-off business. We are very pleased to continue our external development with this strategic acquisition. Once we have received the approval of the regulator, this 21st acquisition will foster our position as a leading provider of legacy solutions in the market.” Aditya Dutt, Senior Vice President of RenaissanceRe, said “We are pleased to enter into an agreement to sell the UK run-off business to AXA LM, a leading manager of legacy businesses. Divestiture of this legacy portfolio to a high-quality owner allows us to continue focusing on our core business segments.”

The Beta number showed the stock is subject to risk -49% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is 2.7% while ROE for the same period is 13.5% and have seen an average of 14.7% return on investment (ROI). The outstanding share count is 44.83 million shares but the size of available float is 43.43 million shares.

The stock’s current price is lagging SMA-200 by -22.51% which is also -12.89% down from SMA-50. Reducing that period to a shorter term, we see the price is also lagging -7.67% to the SMA-20. Volatility for the week was 3.65%, which was 4.76% in the previous month. The company closed the session with a trading volume of 493.77 thousand shares, below from its average daily trading volume of 399.66 thousand. It has been generating revenue of $4.19 billion while net income posted by the company in last 12 months was $703.5 million.

When looking at performance, we see the stock demonstrating a weekly performance of -10.27% while keeping a monthly performance of 3.86%. Quarterly performance saw a drop of -25.76% and continued the negative trend with a yearly performance of -6.82% while showing YTD performance of -28% which was -24.35% for last six months. The 52-week range for the stock was 113.27 – 202.68 that put its current price at a premium of 24.6% to the 52-week low price whereas it is trading at a discount of -30.37% to the 52-week high price.